{"id":"W3167779332","doi":"10.1200/jco.2021.39.15_suppl.5042","title":"Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"","keywords":"Enzalutamide; Medicine; Pembrolizumab; Abiraterone; Prostate cancer; Cohort; Internal medicine; Oncology; Clinical endpoint; Docetaxel; Cancer; Clinical trial; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004026176,0.0006114251,0.001097535,0.0007788501,0.0002827904,0.0007903749,0.0007596329,0.0005338996,0.001920542],"category_scores_gemma":[0.002190536,0.0004404845,0.001922851,0.0009972146,0.000169042,0.0006652568,0.0005305902,0.0009673089,0.0003036249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009406571,"about_ca_system_score_gemma":0.0007350053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002894524,"about_ca_topic_score_gemma":0.006611368,"domain_scores_codex":[0.9986899,0.0005142952,0.0001342772,0.0002118485,0.0002968457,0.0001528661],"domain_scores_gemma":[0.9981186,0.0003783365,0.0009532413,0.0002077769,0.0001548333,0.0001873008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3233141,0.002892346,0.5317951,0.002095473,0.0284327,0.0004586155,0.0002990424,0.003606368,0.01014656,0.0001441051,0.007549017,0.08926665],"study_design_scores_gemma":[0.01461067,0.01726558,0.9484405,0.0001024019,0.01005212,0.0005178765,0.00006804427,0.00106414,0.001528471,0.00008112254,0.006230948,0.00003814354],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802185,0.005301606,0.0008023545,0.000124811,0.00003743598,0.0007410891,0.0114358,0.00005362529,0.001284794],"genre_scores_gemma":[0.9777093,0.001089016,0.0008696692,0.0002112347,0.00006247994,0.0004226312,0.01867747,0.00001616353,0.0009420231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004026176,"threshold_uncertainty_score":0.02129269,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1760126212142792,"score_gpt":0.4835218128724226,"score_spread":0.3075091916581434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}